Ardx stock zacks

Ardelyx (NASDAQ:ARDX) Upgraded by Zacks Investment ... Zacks Investment Research upgraded shares of Ardelyx (NASDAQ:ARDX) from a sell rating to a hold rating in a report published on Monday morning, Zacks.com reports. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small Ardelyx: 4Q Earnings Snapshot - Houston Chronicle

12 Feb 2020 Some of the daily analyst calls cover stocks to buy, while some calls cover as the Bull of the Day at Zacks, which said that the e-commerce giant looks Ardelyx Inc. (NASDAQ: ARDX) was started with a Buy rating and a $13  Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Ardelyx Inc have a median target of 13.00, with a high estimate of 15.00 and a low  12 Aug 2015 After trading began at $10.66 the stock was seen hitting $11.88 as a peak level price targets on shares of Ardelyx (NASDAQ: ARDX) in the last few weeks: 8/20/ 2015 – Ardelyx was downgraded by analysts at Zacks from a  23 Nov 2019 Zacks Rank: This rating systems for stocks, mutual funds, and ETFs can point investors to investments they can potentially include in their own  Real time Ardelyx (ARDX) stock price quote, stock graph, news & analysis. Ardelyx, Inc. - ARDX - Stock Price Today - Zacks View Ardelyx, Inc. ARDX investment & stock information. Get the latest Ardelyx, Inc. ARDX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

ARDX - Ardelyx Stock Interactive Chart - Barchart.com

View detailed financial information, real-time news, videos, quotes and analysis on Ardelyx Inc. (NASDAQ:ARDX). Explore commentary on Ardelyx Inc. and hear what the … ARDX Stock | ARDELYX Stock Price Today | Markets Insider ARDX: Get the latest Ardelyx stock price and detailed information including ARDX news, historical charts and realtime prices. Ardelyx, Inc. Common Stock (ARDX) Real-Time Stock Quote ... ARDX's NASDAQ Last Sale (NLS) "Last Sale" is the price at which a stock last traded during regular market hours. NLS Volume "Volume" is the number of shares of the stock traded on the listing exchange during regular trading hours. Previous Close Today's High / Low 52 Week High / Low Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates ...

ARDX Stock Price, Forecast & News (Ardelyx) | MarketBeat

ARDELYX, INC. : Stock Market News and Information | ARDX ... FREMONT, Calif. (AP) _ Ardelyx Inc. (ARDX) on Friday reported a loss of $19.8 million in its fourth quarter. On a per-share basis, the Fremont, California-based company said it had a loss of 28 cents.. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share. Ardelyx (ARDX) In Focus: Stock Moves 8.3% Higher ... Ardelyx, Inc. (NASDAQ: ARDX) was a big mover last session, as the company saw its shares rise more than 8% on the day.The move came on solid volume too …

Ardelyx (ARDX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of. Ardelyx (ARDX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. the current status translates into a Zacks Rank #3 (Hold) for the stock

Ardelyx (NASDAQ:ARDX) Upgraded at Zacks Investment ... Zacks Investment Research upgraded shares of Ardelyx (NASDAQ:ARDX) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. They currently have $6.50 target price on the biopharmaceutical company’s stock. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small … Ardelyx (NASDAQ:ARDX) Raised to Buy at Zacks Investment ... Zacks Investment Research upgraded shares of Ardelyx (NASDAQ:ARDX) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. The firm currently has $6.50 price objective on the biopharmaceutical company’s stock. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates ... Ardelyx (ARDX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of. Ardelyx (ARDX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. the current status translates into a Zacks Rank #3 (Hold) for the stock Ardelyx (NASDAQ:ARDX) Downgraded to “Sell” at Zacks ...

ARDX: Get the latest Ardelyx stock price and detailed information including ARDX news, historical charts and realtime prices.

Ardelyx, Inc. Common Stock (ARDX) Earnings Report Date ... Find the latest Earnings Report Date for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. Looking for additional market data? Our vendor, Zacks … ARDX - Ardelyx Inc Stock quote - CNNMoney.com Find real-time ARDX - Ardelyx Inc stock quotes, company profile, news and forecasts from CNN Business. Find real-time ARDX - Ardelyx Inc stock quotes, company profile, news and … Ardelyx Inc. - NASDAQ:ARDX - Stock Quote & News - TheStreet View detailed financial information, real-time news, videos, quotes and analysis on Ardelyx Inc. (NASDAQ:ARDX). Explore commentary on Ardelyx Inc. and hear what the … ARDX Stock | ARDELYX Stock Price Today | Markets Insider

Zacks Investment Research upgraded shares of Ardelyx (NASDAQ:ARDX) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. The firm currently has $6.50 price objective on the biopharmaceutical company’s stock. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates ... Ardelyx (ARDX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of. Ardelyx (ARDX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. the current status translates into a Zacks Rank #3 (Hold) for the stock Ardelyx (NASDAQ:ARDX) Downgraded to “Sell” at Zacks ... Ardelyx (NASDAQ:ARDX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday, Zacks.com reports. According to Zacks, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat … Ardelyx, Inc. (ARDX) Interactive Stock Chart - Yahoo Finance Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 221.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock? Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in